Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Trade Group Calls For Relaxation of Regulation To Boost Foreign Medical Device Import

This article was originally published in PharmAsia News

Executive Summary

Aiming to erase the medical device lag in Japan, the Expert Committee on Foreign Direct Investment to Japan, a trade and economic promotional organization, released a proposal to increase efficiency in the medical device review and approval process. The committee calls for an increased budget to strengthen the workforce and reduce unnecessary ministerial level reviews for some foreign devices. The committee also calls to revise operational rules of the Ministry of Health, Labor and Welfare's Food and Drug Safety Council, which controls the final phase in a review process. The summary will be submitted to the Council on Economy and Fiscal. (Click here for more - Japanese language) "Expert Committee Calls For Relaxation In Regulation To Boost Foreign Medical Device Entry" - Sankei News (4/18/08)

You may also be interested in...



Coronavirus Update: Moderna Still Confident Of November Readout

The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.

Latest European Commission Document Focuses On New Rapid Antigen Tests for COVID-19

With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use

Amgen Warns Against Conflating Oncology And Inflammation Biosimilars

Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel